MedTrace Logo

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

NCT05759546 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-02-06

No results posted yet for this study

Summary

This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.

Conditions

  • Breast Cancer Metastatic

Interventions

DRUG

Fluzoparib

Parp inhibitor

DRUG

Dalpiciclib

CDK4/6 inhibitor

DRUG

Fulvestrant/AI

Endocrine therapy

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    collaborator OTHER

  • First Hospital of China Medical University

    collaborator OTHER

  • Sun Yat-sen University

    collaborator OTHER

  • First Affiliated Hospital Xi'an Jiaotong University

    collaborator OTHER

  • Liaoning Cancer Hospital & Institute

    collaborator OTHER

  • Chongqing University Cancer Hospital

    collaborator OTHER

  • Northern Jiangsu People's Hospital

    collaborator OTHER

  • Fujian Medical University Union Hospital

    collaborator OTHER

  • Ningbo Medical Center Lihuili Hospital

    collaborator OTHER_GOV

  • Shanghai First Maternity and Infant Hospital

    collaborator OTHER

  • Shanghai 6th People's Hospital

    collaborator OTHER

  • Affiliated Hospital of Nantong University

    collaborator OTHER

  • Fudan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2025-11-01
Completion
2027-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05759546 on ClinicalTrials.gov